Israeli company Teva Pharmaceuticals could be forced to pay more than $2 billion in damages for selling a generic version of Nycomed and Pfizer’s heartburn reliever Protonix before the drug’s patent exclusivity expired in the US.
If you have already subscribed please login.
If you have any technical issues please email tech support.
Teva, Pfizer, Nycomed, Protonix, generic, damages
